Tango Therapeutics TNGX Cash Flow Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| -$101.59M+22.0% | -$130.3M-28.1% | -$101.74M+5.9% | -$108.18M-85.8% | ||
| $2.28M-8.7% | $2.5M+3.5% | $2.42M+50.2% | $1.61M+84.4% | ||
| $26.43M-8.5% | $28.9M+51.5% | $19.08M+34.1% | $14.23M+81.7% | ||
| -$138.89M-5.6% | -$131.5M-11.5% | -$117.98M-8.2% | -$109.08M-83.2% | ||
| $1.05M+39.0% | $754K-50.6% | $1.53M-80.2% | $7.69M+319% | ||
| -$40.87M-147% | $86.13M— | —— | —— | ||
| $222.5M+367% | $47.66M-42.2% | $82.41M+5,003% | $1.62M— | ||
| $42.75M+1,768% | $2.29M-60.9% | $5.85M+107% | -$85.74M— | ||
| -$139.93M-5.8% | -$132.26M-10.7% | -$119.51M-2.3% | -$116.77M-90.3% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does Tango Therapeutics's cash flow data come from?
- Every line is extracted from Tango Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.